Publications by authors named "Utkarsh Goel"

Claim this Profile
T
The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis.
Matthew J Rees, Jack Khouri, Ariel F Grajales-Cruz, Saurabh S Zanwar, Utkarsh Goel

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.
Aimaz Afrough, Danai Dima, Beatrice Razzo, Utkarsh Goel, Aishwarya Sannareddy

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment.
Danai Dima, Aimaz Afrough, Utkarsh Goel, Ariel F Grajales-Cruz, Jack Khouri

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an Endothelial Activation and Stress Index (EASIX)-based predictive model for cytokine release syndrome and neurotoxicity after B-cell maturation antigen directed chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma.
Utkarsh Goel, Danai Dima, James A Davis, Aliya Rashid, William Wesson

Bone Marrow Transplant· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.
Danai Dima, Mariola A Vazquez-Martinez, James A Davis, Utkarsh Goel, Aimaz Afrough

Blood Cancer J· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of prescription and discontinuation of glucagon-like peptide-1 receptor agonists among patients with irritable bowel syndrome.
Misha Gautam, Utkarsh Goel, Abbas Bader, Samiya Azim, Noor Hassan

Ann Gastroenterol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14-Year Experience of an Academic Center.
Danai Dima, Utkarsh Goel, Fauzia Ullah, Beth Faiman, Diana Basali

Hematol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.
Oren Pasvolsky, Danai Dima, Lei Feng, Wenli Dong, Tiffany Richards, Utkarsh Goel

Blood Cancer J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SOHO State of the Art Updates and Next Questions | Contemporary Role of Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Era of Cellular Therapies.
Utkarsh Goel, Agrima Mian, Craig S Sauter

Clin Lymphoma Myeloma Leuk· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy.
Utkarsh Goel, Saurabh Zanwar, Andrew John Cowan, Rahul Banerjee, Jack Khouri

Cancer Manag Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Prior Selinexor Exposure on Outcomes of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Exploratory Analysis.
Bruno Almeida Costa, Danai Dima, Tomer Mark, Norah Layla Sadek, Stephen Ijioma, Utkarsh Goel

J Clin Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis.
Utkarsh Goel, Danai Dima, James Davis, Nausheen Ahmed, Hira Shaikh

Eur J Haematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retreatment of multiple myeloma with previously refractory drugs.
Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi

Blood Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Annals Graphic Medicine - Two-Factor Authentication.
Utkarsh Goel

Ann Intern Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies.
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis Buadi

Clin Lymphoma Myeloma Leuk· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.
Danai Dima, Michael Hughes, Mark Orland, Fauzia Ullah, Utkarsh Goel

Amyloid· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.
Danai Dima, Utkarsh Goel, Aishwarya Sannareddy, Nnaemeka Ibeh, Fauzia Ullah

Hematol Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma.
Danai Dima, Razan Mansour, James A Davis, Megan Minchak, Utkarsh Goel

Eur J Haematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bilingual.
Utkarsh Goel

Natl Med J India· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy.
Danai Dima, Al-Ola Abdallah, James A Davis, Hussein Awada, Utkarsh Goel

Blood Cancer J· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide.
Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi

Blood Cancer J· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis K Buadi

Blood Cancer J· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis K Buadi

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival.
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis K Buadi

Am J Hematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma.
Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi

Blood Cancer J· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis